With a lack of published studies helping to quantify key tasks for oncology pharmacists, the Hematology/Oncology Pharmacy Association (HOPA), in partnership with the Hematology/Oncology Practice and Research Network (PRN) of the American College of Clinical Pharmacy (ACCP), surveyed hem/onc pharmacists with the goal of creating a consensus on the time necessary to complete common patient and non-patient care-related responsibilities.

The resulting research article represents the first comprehensive consensus statements on the average time for a U.S.-based oncology pharmacist to complete common care-related tasks. These endorsed statements may be utilized in measuring and evaluating hem/onc pharmacist workload and productivity.

The process and resulting consensus statements have been published in the Journal of Oncology Pharmacy Practice.


Authors: Shawn P. Griffin, PharmD, BCOP; Jessie Signorelli, PharmD, BCOP; Farah Raheem, PharmD, BCOP; Kristin Adler, M.Ed; Lydia L. Benitez, PharmD, BCOP; Rose M. Cheng, PharmD, BCOP; Emily Dotson, PharmD, BCOP; Marielle Fares, PharmD; Beejal R. Ganti, PharmD, BCOP; Erin Hickey Zacholski, PharmD, BCOP; Aubrey R. Lasko, PharmD, BCOP; Amanda B. Lewallen, PharmD, BCOP; Alia C. Lynch, PharmD, BCOP; Nikola Paulic, PharmD, BCOP; David Quach, PharmD, BCPS, BCOP; Vishnuprabha Vogel, PharmD, BCOP; Matt Yacobucci, PharmD, BCOP; and Grazyna Riebandt, PharmD, BCOP

Read the full article here

U.S. Capitol Building
Advocacy

What HOPA Members Should Know About the End of the 2025 U.S. Government Shutdown

On Wednesday, November 12, Congress passed a continuing resolution to re-open the government after a record 43-day shutdown. Here's what HOPA members should know about the bill and what's happening next.

Map of the sub-Saharan African region
Advocacy

HOPA Endorses ISOPP & UICC Statement on Ensuring International Cancer Drug Quality and Equity

ISOPP and UICC recently released a statement calling for quality and equity of cancer treatments in sub-Saharan Africa. HOPA has joined with oncology and pharmacy organizations worldwide to endorse their statement.

Images of DNA strands for DPYD genetic testing
Advocacy

HOPA Supports FDA Box Label Changes for DPYD Testing

We support the FDA's updated guidance concerning DPD deficiency and fluoropyrimidine drugs, and urge healthcare providers to integrate DPYD genetic testing into clinical practice.